"Long moments of boredom punctuated by moments of sheer terror" is a relatively common expression used in reference to war, but it can also apply to biotech investing, to a limited extent. Stocks like Neurocrine Biosciences (NASDAQ:NBIX) are inarguably driven in large part by relatively infrequent news on clinical trial outcomes and partnering arrangements, with the shares left to drift on speculation and overall biotech sentiment in the long spaces between.
Neurocrine management is certainly not just sitting on its hands as they work to put '854 into Phase III development for tardive dyskinesia and Phase II development for Tourette's, and as partner AbbVie (NYSE:ABBV) moves Elagolix through clinical trials in endometriosis and uterine fibroids. Between...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|